Iovance Biotherapeutics (IOVA) Gross Profit (2023 - 2025)
Historic Gross Profit for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $29.0 million.
- Iovance Biotherapeutics' Gross Profit rose 717.91% to $29.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 12639.79%. This contributed to the annual value of $40.1 million for FY2024, which is 51893.16% up from last year.
- Per Iovance Biotherapeutics' latest filing, its Gross Profit stood at $29.0 million for Q3 2025, which was up 717.91% from $3.3 million recorded in Q2 2025.
- In the past 5 years, Iovance Biotherapeutics' Gross Profit registered a high of $29.0 million during Q3 2025, and its lowest value of -$6.5 million during Q1 2024.
- In the last 3 years, Iovance Biotherapeutics' Gross Profit had a median value of -$339500.0 in 2024 and averaged $4.8 million.
- Examining YoY changes over the last 5 years, Iovance Biotherapeutics' Gross Profit showed a top increase of 135496.18% in 2025 and a maximum decrease of 717.91% in 2025.
- Quarter analysis of 3 years shows Iovance Biotherapeutics' Gross Profit stood at -$3.9 million in 2023, then soared by 232.84% to $5.2 million in 2024, then soared by 461.81% to $29.0 million in 2025.
- Its Gross Profit was $29.0 million in Q3 2025, compared to $3.3 million in Q2 2025 and -$417000.0 in Q1 2025.